14 December 2017
EMA/192236/2017
Human Medicines Evaluation Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Yervoy	
ipilimumab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s)in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH UNITED KINGDOM
Procedure	
Procedure number:	EMEA/H/C/002213/II/0044

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

- the development of this product has complied with all measures in the agreed paediatric investigation plan PIP P/0003/2017. All studies in the agreed paediatric investigation plan PIP P/0003/2017 were conducted after the entry into force of that Regulation,

- the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan PIP P/0003/2017 is included in the technical dossier.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact